TP53BP2 and lymphoma: Attenuation of the ASPP2 wildtype isoforms is frequently observed in various tumors such as breast cancer [6], high-grade lymphoma [8] and acute leukemia [9], where low ASPP2 expression levels are associated with a more aggressive disease, therapy failure, and poor clinical outcome.